Umoja Biopharma

Umoja Biopharma is developing a transformative approach to CAR T therapy by using its proprietary VivoVec platform to engineer a patient's T cells in vivo, eliminating the need for complex ex vivo cell manufacturing. This strategy has the potential to make CAR T treatments faster, more accessible, and scalable. The company is advancing a clinical pipeline in oncology, has secured FDA Fast Track designation for its lead program, and has invested in in-house lentiviral vector manufacturing to control its supply chain. With key appointments to its board and recognition as a promising biotech, Umoja is positioning itself as a leader in next-generation cell therapy.

VivoVec™ in vivo lentiviral vector platform designed to generate CAR T cells directly inside a patient's body.

Umoja competes with major pharmaceutical companies marketing ex vivo CAR T therapies (e.g., Novartis, Gilead) and a growing field of biotechs developing next-gen approaches, including allogeneic 'off-the-shelf' CAR T companies and other in vivo engineering platforms like those from Capstan Therapeutics and Ensoma.